Daily Management Review

Investors betting on Moderna shares fall lose nearly $2B in total


Investors betting on the fall in shares of the American biotech company Moderna lost almost $ 2 billion this year. On Monday, Moderna announced that its coronavirus vaccine was nearly 95 percent effective, after which its shares rose by 15 percent.

Investors who bet on the fall in shares of the American biotech company Moderna lost about $ 1.85 billion this year, Bloomberg reports with reference to the analytical company S3 Partners. In November alone, such investors lost $ 790 million.

Moderna is one of the companies developing a coronavirus vaccine. The firm said on Monday that interim results from a third phase of trials of the vaccine were 94.5% effective. Moderna CEO Stéphane Bancel announced a "turning point" in the development process. The growth in the value of the company’s securities reached 15%, Bloomberg notes.

So far, Moderna has reported the best test results among vaccine developers. Last week, Pfizer and BioNTech reported that a third phase of trials has demonstrated 90 percent effectiveness of their vaccine. The developers of the Russian vaccine against COVID-19 Sputnik V estimated its effectiveness at 92%.

The news about the effectiveness of the vaccine also helped go up companies dependent on the resumption of economic activity, while securities that benefited from the introduction of self-isolation regimes lagged behind them, Bloomberg notes. Thus, the shares of the Zoom videoconferencing service became 3.25% cheaper and cost $ 390.48 per share. Last week, following news of the effectiveness of the vaccine from Pfizer and BioNTech, the Zoom founder's wealth fell by almost 20%.

source: bloomberg.com